Skip to main content
Top
Published in: Journal of Endocrinological Investigation 12/2016

01-12-2016 | Original Article

The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study

Authors: L. Bartalena, E. Masiello, F. Magri, G. Veronesi, E. Bianconi, F. Zerbini, M. Gaiti, E. Spreafico, D. Gallo, P. Premoli, E. Piantanida, M. L. Tanda, M. Ferrario, P. Vitti, L. Chiovato

Published in: Journal of Endocrinological Investigation | Issue 12/2016

Login to get access

Abstract

Objective

The Merseburg triad (hyperthyroidism, goiter, and orbitopathy) characterizes classical description of Graves’ disease (GD). Aim of this observational, longitudinal study was to evaluate the current clinical features of newly diagnosed GD in Italy.

Materials and methods

In two Northern Italy centers (Varese and Pavia), 283 consecutive patients (211 women, 72 men; mean age 47.4 years) with newly diagnosed GD were recruited in the years 2010–2014. Diagnosis was based on established criteria, and thyroid volume was assessed by ultrasonography. A clinical severity score (CSS) to assess the overall disease severity was developed by grading each component of the Merseburg triad.

Results

At diagnosis, 45 % of patients had no goiter, and 30 % had a small goiter. The proportion of goitrous patients was much lower than in two Italian studies performed 20–30 years ago. Hyperthyroidism was subclinical in 16 % and mild in 29 % of patients, and Graves’ orbitopathy was present in 20 %, usually mild, and active in only 2.5 % of patients. Using the CSS, less than half (44 %) of the patients had severe GD, while 22 % had mild and 34 % moderate disease. CSS was associated with a significantly higher risk of poorly controlled hyperthyroidism at 6 months.

Conclusions

In Italy, a relevant proportion of Graves’ patients at diagnosis have mild to moderate GD; about half of them have no goiter, slightly less than one-fifth have subclinical hyperthyroidism, and only 20 % have GO. Thus, the clinical phenotype of GD is milder than in the past, possibly due to both earlier diagnosis and treatment, and improved iodine nutrition.
Literature
1.
go back to reference Bartalena L (2013) Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9:724–734CrossRefPubMed Bartalena L (2013) Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9:724–734CrossRefPubMed
3.
go back to reference Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2015) Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest 38:283–294CrossRefPubMed Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2015) Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest 38:283–294CrossRefPubMed
5.
go back to reference Von Basedow KA (1840) Exophthalmos durch hypertrophie des zellgewebesin der Augenhole. Wochenschr Ges Heilk Berl 6:197 Von Basedow KA (1840) Exophthalmos durch hypertrophie des zellgewebesin der Augenhole. Wochenschr Ges Heilk Berl 6:197
6.
go back to reference Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37:691–700CrossRefPubMed Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37:691–700CrossRefPubMed
7.
go back to reference Tanda ML, Piantanida E, Liparulo L, Veronesi G, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98:1443–1449CrossRefPubMed Tanda ML, Piantanida E, Liparulo L, Veronesi G, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98:1443–1449CrossRefPubMed
8.
go back to reference Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 36:444–449PubMed Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest 36:444–449PubMed
9.
go back to reference Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F (2015) Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology consensus statement. J Endocrinol Invest 38:481–487CrossRefPubMedPubMedCentral Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F (2015) Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology consensus statement. J Endocrinol Invest 38:481–487CrossRefPubMedPubMedCentral
10.
go back to reference Laurberg P, Bucholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J (1986) Goitre size and outcome of medical treatment of Graves’ disease. Acta Endocrinol (Copenh) 111:39–43 Laurberg P, Bucholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J (1986) Goitre size and outcome of medical treatment of Graves’ disease. Acta Endocrinol (Copenh) 111:39–43
11.
go back to reference Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 7:369–375CrossRefPubMed Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 7:369–375CrossRefPubMed
12.
go back to reference Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285CrossRefPubMed Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285CrossRefPubMed
13.
go back to reference Marinò M, Chiovato L, Pinchera A (2010) Graves’ disease. In: Jameson JL, DeGroot LJ (eds) Endocrinology—adult and pediatric, vol II, 6th edn. Saunders Elsevier, Philadelphia, pp 1527–1558 Marinò M, Chiovato L, Pinchera A (2010) Graves’ disease. In: Jameson JL, DeGroot LJ (eds) Endocrinology—adult and pediatric, vol II, 6th edn. Saunders Elsevier, Philadelphia, pp 1527–1558
14.
go back to reference Wiersinga WM (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79:145–151CrossRef Wiersinga WM (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79:145–151CrossRef
15.
go back to reference Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R (1989) Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 121(Suppl 2):185–189 Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R (1989) Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 121(Suppl 2):185–189
16.
go back to reference Tallstedt L, Lundell G, Blomgren H, Bring J (1994) Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494–497CrossRefPubMed Tallstedt L, Lundell G, Blomgren H, Bring J (1994) Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494–497CrossRefPubMed
17.
go back to reference Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab 90:5321–5323CrossRefPubMed Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab 90:5321–5323CrossRefPubMed
18.
go back to reference Valente WA, Vitti P, Rotella CM, Vaughan MM, Aloj SM, Grollman EF, Ambesi-impiombato FS, Kohn LD (1983) Antibodies that promote thyroid growth. A distinct population of thyroid-stimulating autoantibodies. N Engl J Med 309:1028–1034CrossRefPubMed Valente WA, Vitti P, Rotella CM, Vaughan MM, Aloj SM, Grollman EF, Ambesi-impiombato FS, Kohn LD (1983) Antibodies that promote thyroid growth. A distinct population of thyroid-stimulating autoantibodies. N Engl J Med 309:1028–1034CrossRefPubMed
19.
go back to reference Chiovato L, Hammond LJ, Hanafusa T, Pujol-Borrell R, Doniach D, Bottazzo GF (1983) Detection of thyroid growth immunoglobulins (TGI) by [3H]-thymidine incorporation in cultured rat thyroid follicles. Clin Endocrinol (Oxf) 19:581–590CrossRef Chiovato L, Hammond LJ, Hanafusa T, Pujol-Borrell R, Doniach D, Bottazzo GF (1983) Detection of thyroid growth immunoglobulins (TGI) by [3H]-thymidine incorporation in cultured rat thyroid follicles. Clin Endocrinol (Oxf) 19:581–590CrossRef
20.
go back to reference Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Bulow Pedersen I, Linding Andersen S (2014) Association between TSH-receptor autoimmunity, hyperthyroidism, goitre, and orbitopathy in 208 patients included in the Remission and Sustenance in Graves’ Disease Study. J Thyroid Res. doi:10.1155/2014/165487 PubMedPubMedCentral Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Bulow Pedersen I, Linding Andersen S (2014) Association between TSH-receptor autoimmunity, hyperthyroidism, goitre, and orbitopathy in 208 patients included in the Remission and Sustenance in Graves’ Disease Study. J Thyroid Res. doi:10.​1155/​2014/​165487 PubMedPubMedCentral
21.
go back to reference Raber W, Kmen E, Waldhausl W, Vierhapper H (2000) Medical therapy of Graves’ disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. Eur J Endocrinol 142:117–124CrossRefPubMed Raber W, Kmen E, Waldhausl W, Vierhapper H (2000) Medical therapy of Graves’ disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. Eur J Endocrinol 142:117–124CrossRefPubMed
22.
go back to reference Glinoer D, de Nayer P, Bex M, Belgian Collaborative Study Group on Graves’ Diseaase (2001) Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144:475–483CrossRefPubMed Glinoer D, de Nayer P, Bex M, Belgian Collaborative Study Group on Graves’ Diseaase (2001) Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144:475–483CrossRefPubMed
23.
go back to reference Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Agabiti-Rosei E (2007) Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study. Endocr J 54:713–720CrossRefPubMed Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Agabiti-Rosei E (2007) Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study. Endocr J 54:713–720CrossRefPubMed
24.
go back to reference Goichot B, Caron P, Landron F, Bouée S (2016) Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationship with age, aetiology and hormonal parameters. Clin Endocrinol (Oxf) 84:445–451CrossRef Goichot B, Caron P, Landron F, Bouée S (2016) Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationship with age, aetiology and hormonal parameters. Clin Endocrinol (Oxf) 84:445–451CrossRef
25.
go back to reference Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S (2016) The natural history of subclinical hyperthyroidism in Graves’ disease: the rule of thirds. Thyroid 101:1381–1389 Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S (2016) The natural history of subclinical hyperthyroidism in Graves’ disease: the rule of thirds. Thyroid 101:1381–1389
26.
go back to reference Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM (2016) Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 26:765–769 Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM (2016) Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 26:765–769
27.
go back to reference Aghini-Lombardi F, Pinchera A, Antonangeli L, Rago T, Fenzi GF, Nanni P, Vitti P (1993) Iodized salt prophylaxis of endemic goiter: an experience in Toscana (Italy). Acta Endocrinol (Copenh) 129:497–500 Aghini-Lombardi F, Pinchera A, Antonangeli L, Rago T, Fenzi GF, Nanni P, Vitti P (1993) Iodized salt prophylaxis of endemic goiter: an experience in Toscana (Italy). Acta Endocrinol (Copenh) 129:497–500
Metadata
Title
The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study
Authors
L. Bartalena
E. Masiello
F. Magri
G. Veronesi
E. Bianconi
F. Zerbini
M. Gaiti
E. Spreafico
D. Gallo
P. Premoli
E. Piantanida
M. L. Tanda
M. Ferrario
P. Vitti
L. Chiovato
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 12/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-016-0516-7

Other articles of this Issue 12/2016

Journal of Endocrinological Investigation 12/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.